Abeona Therapeutics (NASDAQ:ABEO) Director Purchases $34,350.00 in Stock

Key Points

  • Director Faith Charles bought 15,000 shares at an average price of $2.29, spending $34,350 and increasing her stake by 8.5% to 191,407 shares.
  • Abeona reported a quarterly loss of $0.08 per share, better than the $0.17 loss analysts expected, but revenue of $13.49 million fell short of the $14.82 million consensus.
  • Analysts’ consensus rating was Moderate Buy with a $21 price target, although some earnings estimates were cut and the company remains loss-making.

Abeona Therapeutics Inc. (NASDAQ:ABEO - Get Free Report) Director Faith Charles acquired 15,000 shares of the company's stock in a transaction that occurred on Friday, November 13th. The shares were acquired at an average cost of $2.29 per share, for a total transaction of $34,350.00. Following the purchase, the director directly owned 191,407 shares in the company, valued at $438,322.03. This trade represents a 8.50% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Abeona Therapeutics Trading Up 7.4%

ABEO stock opened at $2.60 on Tuesday. Abeona Therapeutics Inc. has a 1-year low of $2.09 and a 1-year high of $7.65. The firm has a market cap of $148.59 million, a PE ratio of -2.43 and a beta of 1.50. The business's 50-day moving average price is $4.63 and its two-hundred day moving average price is $5.38.

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last announced its quarterly earnings results on Monday, November 9th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.09. Abeona Therapeutics had a negative return on equity of 44.82% and a negative net margin of 160.30%. The company had revenue of $13.49 million during the quarter, compared to the consensus estimate of $14.82 million. On average, analysts forecast that Abeona Therapeutics Inc. will post -0.97 earnings per share for the current year.

Latest Abeona Therapeutics News




These are some of the ABEO news items that stood out recently:

  • Positive Sentiment: Director Faith Charles bought 15,000 shares for about $34,350, increasing her stake by 8.5% to 191,407 shares. The insider purchase may be viewed as a confidence signal. SEC filing
  • Neutral Sentiment: HC Wainwright maintained its Buy rating. It raised its FY2026 EPS estimate to a loss of $0.96 from $1.15, while forecasting a $0.82 loss per share for FY2027. Abeona Therapeutics analyst coverage
  • Negative Sentiment: The analyst lowered estimates across Q1–Q4 2027, including cutting FY2027 EPS to a loss of $0.82 from $0.49. These revisions suggest a weaker earnings outlook and could weigh on shares, partially offsetting the insider buying.

Wall Street Analysts Forecast Growth

ABEO has been the subject of several research analyst reports. Weiss Ratings lowered Abeona Therapeutics from a "sell (d)" rating to a "sell (d-)" rating in a research report on Tuesday, November 10th. Cantor Fitzgerald raised their target price on shares of Abeona Therapeutics from $28.00 to $30.00 and gave the stock an "overweight" rating in a report on Friday, September 18th. Oppenheimer reaffirmed an "outperform" rating and issued a $21.00 price target (down from $22.00) on shares of Abeona Therapeutics in a research note on Friday, August 14th. Roth Capital began coverage on shares of Abeona Therapeutics in a research note on Thursday, September 17th. They issued a "buy" rating and a $17.00 price target on the stock. Finally, UBS Group reiterated a "buy" rating on shares of Abeona Therapeutics in a report on Friday, September 25th. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $21.00.

Check Out Our Latest Report on Abeona Therapeutics

Hedge Funds Weigh In On Abeona Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. AIGH Capital Management LLC bought a new position in Abeona Therapeutics during the 3rd quarter worth about $15,225,000. AWM Investment Company Inc. acquired a new position in shares of Abeona Therapeutics during the second quarter worth about $9,184,000. Nan Fung Trinity HK Ltd. boosted its position in shares of Abeona Therapeutics by 336.6% during the third quarter. Nan Fung Trinity HK Ltd. now owns 552,270 shares of the biopharmaceutical company's stock worth $2,899,000 after buying an additional 425,770 shares during the period. Simplify Asset Management Inc. acquired a new position in shares of Abeona Therapeutics during the third quarter worth about $1,451,000. Finally, Bank of New York Mellon Corp bought a new position in shares of Abeona Therapeutics during the second quarter worth about $1,262,000. 80.56% of the stock is owned by institutional investors and hedge funds.

About Abeona Therapeutics

(Get Free Report)

Abeona Therapeutics, Inc. is a biotechnology company focused on developing cell and gene therapies for serious and rare diseases. Its work includes treatments designed to address the underlying genetic causes of disease. The company's lead product, ZEVASKYN (prademagene zamikeracel), is an autologous gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa, a rare inherited skin disorder. Made from a patient's skin cells, the therapy uses genetic modification to help cells produce type VII collagen and is applied to wounds.

Featured Articles

Insider Buying and Selling by Quarter for Abeona Therapeutics (NASDAQ:ABEO)

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].

Insider Buying or Selling at Abeona Therapeutics?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Abeona Therapeutics and related companies.
Free Insider Buying and Selling Newsletter
Enter your email address below to receive InsiderTrades.com's daily insider buying and selling report.
From Our Partners

Most Read This Month

Recent Articles